A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

Journal of Neuro-Oncology

Volumn 133, Issue 3, 2017, Pages 589-594

  Kumthekar, Priya ^a   Grimm, Sean ^a   Chandler, James ^b   Mehta, Minesh ^c   Marymont, Maryanne ^a   Levy, Robert ^d   Muro, Kenji ^e   Helenowski, Irene ^f   McCarthy, Katie ^b   Fountas, Leanne ^b   Raizer, Jeffrey ^a  

^a ABBOTT LABORATORIES   (United States)

^b Northwestern Medicine   (United States)

^c MIAMI CANCER INSTITUTE   (United States)

^d Advocate Health Department of Neurosurgery ^*  (United States)

^e Departments of Neurosurgery   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anaplastic astrocytoma; Arsenic; Arsenic trioxide; GBM; Glioma

Indexed keywords

ALANINE AMINOTRANSFERASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GRANISETRON; ONDANSETRON; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; ORGANOARSENIC DERIVATIVE; OXIDE;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG SAFETY; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; LOADING DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RADIATION DOSE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIAGNOSTIC IMAGING; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ARSENICALS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019195778     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-017-2469-x     Document Type: Article

References (19)

1. Stupp R et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
2. Wick W (2015) Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. ASCO Conference
3. Dolecek TA et al (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Onco 14(Suppl 5):v1–v49
4. Gilbert MR, Sulman EP, Mehta MP (2014) Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(21):2048–2049
5. Kizilbash SH et al (2014) The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol 120(1):85–93
6. Miller WH Jr., et al (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62(14):3893–3903
7. Yedjou C et al (2010) Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol 3:28
8. Ning S, Knox SJ (2006) Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys 65(2):493–498
9. Ning S, Knox SJ (2004) Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys 60(1):197–203
10. Zhen Y et al (2010) Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett 292(1):64–72
11. Nasr R (2010) Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting. Int J Hematol 91(5):742–747
12. Zhou W et al (2015) Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget 6(35):37300–37315
13. Fatoo A et al (2011) Understanding the role of tumor stem cells in glioblastoma multiforme: a review article. J Neurooncol 103(3):397–408
14. Lim SK et al (2011) Glioblastoma multiforme: a perspective on recent findings in human cancer and mouse models. BMB Rep 44(3):158–164
15. Grimm SA et al (2012) Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. J Neurooncol 110(2):237–243
16. Macdonald DR et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280
17. Nayak L et al (2015) Radiotherapy and temozolomide for anaplastic astrocytic gliomas. J Neurooncol 123(1):129–134
18. Iwanami A et al (2013) PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci USA 110(11):4339–4344
19. Iwanami A et al (2013) Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle 12(10):1473–1474